CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
Entry into a Material Definitive Agreement
On June 29, 2018, Cidara Therapeutics, Inc. (the “Company”) entered into a Fourth Amendment to its lease (the “Fourth Lease Amendment”) with Nancy Ridge Technology Center, L.P (the “Landlord”) to amend its existing facilities lease. The Fourth Lease Amendment extends the term of the lease by an additional 36 months through December 31, 2021. Beginning on January 1, 2019, the Company’s base monthly rent will increase to approximately $69,650, which will increase by a rate of 3% annually thereafter. The Company has also been granted an option, exercisable prior to September 30, 2019, to expand its leased premises on the same terms as the current lease, subject to compliance with specified conditions.
The foregoing description of the Fourth Lease Amendment is subject to, and qualified in its entirety by reference to, the full text of the Fourth Lease Amendment, a copy of which is filed as Exhibit 10.1 to this report.
|
Item 9.01. |
Financial Statements and Exhibits |
(d)Exhibits.
Cidara Therapeutics, Inc. ExhibitEX-10.1 2 item101.htm FOURTH AMENDMENT TO LEASE,…To view the full exhibit click here
About CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease.
